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Hypercholesterolemia is a highly prevalent disease often treated with 
statin therapy. Statins lower serum cholesterol level by increasing the level 
of low-density lipoprotein receptors (LDLR) in liver cells, which bind to and 
remove low-density lipoprotein cholesterol (LDL-C). However, up to 39% of 
individuals fail to meet LDL-C goals. There are FDA approved alternatives to 
statins such as Evolocumab (PCSK9 inhibitor), as well as Mipromersen 
(oligonucleotide inhibitor of ApoB synthesis) and Lomitapide (MTTP 
inhibitor). Evolocumab is cost prohibitive and, along with statins, has little to 
no effect in patients with LDLR mutations such as Familial 
Hypercholesterolemia (FH), which is an inherited metabolic disease caused 
by decreased functionality of LDLRs.  Additionally, Mipromersen and 
Lomitapide have FDA hepatotoxic warnings. Therefore, there is a need for 
new drug that lowers cholesterol levels independently from the LDLR 
pathway.  
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In order to find an alternative compound with less toxicity, a small 
molecule screening was conducted using ELISA to measure changes in 
concentration of the major protein component of LDL-C, Apolipoprotein B, 
within the culture medium of iPSC-derived hepatocytes. We have access to 
nearly 120,000 novel molecules from the South Carolina Compound 
Collection (SC3) and tested a 10,000 compound chemically diverse subset of 
this library. Using human iPSC-derived hepatocytes, we aimed to identify 
novel compounds that reduce serum LDL-C level independent from the LDLR 
pathway.  Through the course of the screening, we identified 11 compounds 
that reduced Apolipoprotein B levels, five of which are hypothesized to 




Familial Hypercholesterolemia (FH) is an inherited form of 
hyperlipidemia resulting from loss of function mutations to the low-density-
lipoprotein receptor (LDLR) gene.1, 2  When the organ size is taken into 
account, the liver produces the greatest amount of LDLRs in the body.3 One 
function of the LDLR is believed to be regulation of the secretion and 
degradation of Apolipoprotein B (ApoB), which is used by hepatocytes to form 
the protein core of low-density lipoproteins (LDL).4, 5  Following its formation 
in the liver, very-low-density lipoproteins (VLDL) are secreted into the 
bloodstream where it is converted to LDL through the action of triacylglycerol 
lipase.5    
Every VLDL and LDL particle contains one molecule of ApoB, which 
transports approximately 1600 molecules of cholesterol.1, 6  LDLRs have high 
affinity for LDL and are able to cycle multiple times into the cell and back to 
internalize LDL.3  Without the ability to gauge serum LDL-C levels through 
functional LDLRs, patients with FH show higher levels of ApoB being 
secreted and reduced rates of clearance, resulting in increased levels of 
VLDL, and therefore LDL, found in circulation.5, 7    
FH occurs in heterozygous and homozygous forms.  While 
heterozygosity is more prevalent, affecting approximately 1:500 individuals, 
the phenotype of homozygous individuals is more severe.1, 2  Homozygous 
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individuals have LDL-C levels that are two-to-ten times higher than 
unaffected individuals1, 2, 8 and develop severe early onset cardiovascular 
diseases in childhood that can result in sudden cardiac death by their second 
decade of life if left untreated.2  Incidence of heart attack is known to 
increase proportionately with levels of plasma LDL-C.3, 4    
Many heterozygous individuals can be treated successfully with 
cholesterol lowering drugs such as statins and PCKS9 inhibitors, which 
upregulate LDLR transcription and LDLR protein stability, 
respectively.9  Individual responses to statins vary widely, however, and at 
least 20% of patients, on average, do not meet their LDL-C goals.8, 10  There 
are several different factors which underlie statin resistance, including 
genetics, comorbidities, and interactions with other drugs.11  Additionally, 
these therapies are ineffective in treating patients with homozygous FH 
(HoFH) due to the absence of functional LDLRs.10, 11    
Therapies that target VLDL production result in a reduction of LDL-C 
in HoFH.9 Two such therapies are Lomitapide and Mipromersen, which 
interferes with the production of VLDL and ApoB respectively. 12, 13, 14 
However, both Lomitapide and Mipromersen have FDA warnings for 
detrimental side effects including increased risk of liver damage and fatty 
liver disease.13, 14 As such, there are currently no therapies for individuals 
with HoFH that are known to be safe and effective.  New therapeutic 
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advances need to be developed and employed not only in cases of FH, but also 
in cases where the current standard of care may fall short. 
Induced pluripotent stem cells (IPSC) have the potential to 
revolutionize new therapeutic opportunities.  Primary hepatocytes are 
unsuitable for studying complex functions because they rapidly 
dedifferentiate in culture and lose key hepatic functions.9, 15  IPSCs, however, 
provide an alternative to primary hepatocytes.  IPSCs are somatic cells (e.g. 
skin, fibroblasts, blood) that have been reprogrammed to a pluripotent, 
embryonic stem cell state through the addition of 4 transcription factors, 
known as the Yamanaka factors (OCT4, SOX2, and either NANOG & LIN28 
or KLF4 & MYC),16 and they can be generated from either healthy or 
diseased, patient specific cells.  IPSCs are useful as an alternative to primary 
hepatocytes because the IPSCs can be directed to differentiate into, 
potentially, any somatic cell type through cell culture differentiation 
including hepatocyte-like cells.16, 17  Patient specific IPSCs generated from 
diseased cells have been shown to retain characteristics of that disease after 
differentiation.8, 18  Use of patient specific IPSCs allows for an inexhaustible 
source of disease-modeling cells that can be used to study the biomechanics of 
the disease, as well as investigating potential therapies.  IPSCs have many 
functions in medical research, including disease modeling, drug discovery, 
and preclinical trial testing.9, 16, 18, 19  The inducible nature of IPSCs makes 
them useful in answering disease specific questions.    
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Previous research in our lab has demonstrated the ability to 
successfully utilize both wild-type iPSC-derived hepatocyte-like cells (K3 
iPSCs) and patient-derived HoFH iPSC-derived hepatocyte-like cells as part 
of a compound screening platform.9  Cayo et al have shown that the 
pathophysiology of FH can be recapitulated in patient-derived IPSCs, and 
that these cells are suitable for compound screening.7, 9  During this previous 
screening of a repurposing library, cardiac glycosides were identified as 
having potential use as a drug therapy in cases of hypercholesterolemia, in 
particular for cases of FH.   
It is known that there are alternative routes to the LDLR pathway 
that are employed by the liver to clear LDL-C in excess of what can be 
cleared through the LDLR pathway.6  Cardiac glycosides, along with the 
currently approved therapies, Lomitapide and Mipromersen, function outside 
of the LDLR pathway to reduce LDL-C levels by disrupting the production of 
either Apolipoprotein B or VLDL.9, 13, 14  However, due to the detrimental side 
effects associated with the currently approved drug therapies, it is necessary 
to identify novel compounds that function in lowering levels of LDL-C by 
effecting either the production, secretion, or clearance of Apolipoprotein B or 
VLDL. 	
In this research, we aim to identify small molecules within the RS 
subset of the SC3 library of compounds that will reduce the level of 
Apolipoprotin B protein in the culture medium of wild-type IPSC-derived 
	 5	
hepatocyte-like cells (aim 1), and to identify which of those primary 
compounds function independently of the LDLR pathway to lower 
Apolipoprotein B within the culture medium (aim 2).  
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MATERIALS AND METHODS 
 
Cell Culture 
iPS cells were cultured on p100 plates coated with E-Cadherin Substrate 
(StemAdhere) under hypoxic conditions (4% O2/5% CO2) at 37°C in mTeSR1 
culture medium supplemented with z-FGF.  The culture medium was 
changed daily, and the cells were passaged approximately every 3-5 days. 
 
Hepatocyte Differentiation 
Differentiation of iPS cells was done on Matrigel coated 96-well tissue culture 
plates.  The cells were cultured in mTeSR1 medium for approximately 24 
hours after plating to allow the wells to reach approximately 85-90% 
confluency at which point differentiation may be initiated.  To begin 
differentiation, the cells were cultured for two days (differentiation days 1-2) 
in the following medium: RPMI + B27 (without insulin) + Activin A + BMP4 
+ FGF-2 under normoxic conditions (ambient O2/5% CO2) at 37°C.  For 
differentiation days 3-5, the cells were cultured in the following medium: 
RPMI + B27 (without insulin) + Activin A under normoxic conditions 
(ambient O2/5% CO2) at 37°C.  At differentiation day 5, before replacing the 
culture medium, the cells were treated with Versene/EDTA briefly to prevent 
the monolayer from detaching from the well and aggregating.  For 
differentiation days 6-10, the cells were cultured in the following medium: 
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RPMI + B27 (with insulin) + BMP4 + FGF-2 under hypoxic conditions (4% 
O2/5% CO2) at 37°C.  For differentiation days 11-15, the cells were cultured in 
the following medium: RPMI + B27 (with insulin) + HGF under hypoxic 
conditions (4% O2/5% CO2) at 37°C.  For differentiation days 16-20, the cells 
were cultured in the following medium: HCM + Oncostatin M under normoxic 
conditions (ambient O2/5% CO2) at 37°C.   
 
South Carolina Compound Collection (SC3) Library 
The full SC3 library contains 120,000 chemically diverse small, drug-like 
compounds.  A complex algorithm is utilized to break this full library up into 
smaller libraries.  For the purposes of this screening, we are utilizing the 
Representative Set (or "RS set") of 10,000 unique compounds that are 
chemically representative of the 120,000 compounds found in the full 
library.   
 
Compound Treatment 
At differentiation day 21, exactly 24 hours after changing the culture medium 
on differentiation day 20, the culture medium was collected and transferred 
to new 96-well plates, sealed, and stored at -20°C until ready for further 
testing.  These samples were deemed the “pre-treatment samples”.  Following 
the collection of the pre-treatment samples, the cells were treated with 
either: compound or DMSO (vehicle only) depending on if the well was 
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designated as experimental or control.  These cells were cultured for 24 hours 
under normoxic conditions (ambient O2/5% CO2) at 37°C.  At differentiation 
day 22, exactly 24 hours after then application of compound to the cells, the 
culture medium was collected again and transferred to new 96-well plates, 
sealed, and stored at -20°C until ready for further testing.  These samples 
were deemed the “post-treatment samples”. 
 
Cell Viability 
Following collection of post-treatment samples from validation screening 
plates, cell viability was determined through the use of a commercially 
available cell viability assay (Cell-Titre Glo).  
 
ELISA 
Concentrations of ApoB within the pre and post treatment samples were 
determined through the use of a Human ApoB100 ELISA assay kit from 
Mabtech.  The assays were conducted in 96-well format.  A standard curve 
was included on each plate using ApoB protein from the ELISA kit.  This 
provided a measure of comparison to determine the concentration of ApoB 






The concentration of Apolipoprotein B within each sample, as determined by 
ELISA, was used to determine the [post-treatment sample] : [pre-treatment 
sample] ratio for each compound.  This Apolipoprotein B ratio was 
normalized to the average Apolipoprotein B ratio of DMSO only control 
samples.  Due to the absence of replicates in the primary screening and the 
large number of samples per plate, we conducted z-score analysis on a plate 
to plate basis to identify compounds that reduced concentrations of 
Apolipoprotein B significantly compared to the mean reduction.20  We chose a 
threshold of z-score ≤ -3.0, based on the 3-sigma rule.21  Compounds of 
interest from the primary screening were validated with replicates (n=4).  In 
analyzing the results obtained from validation screening, a student t-test was 
utilized to determine significance (p ≤ 0.05).  A student t-test was also 
utilized to determine compounds that significantly lowered cell viability (p ≤ 
0.05).  Compounds of interest from the validation screening in WT K3 iPSC-
derived hepatocyte-like cells were then validated with replicates (n=4) in JD4 
HoFH iPSC-derived hepatocyte-like cells.  In analyzing the results obtained 
from JD compound screening, a student t-test was utilized to determine 
significance (p ≤ 0.05).  A student t-test was also utilized to determine 






Prior to screening the entire RS subset, the first 1,000 compounds were 
screened to test our approach.  The first 1,000 compounds of the RS subset 
are designated as the RS Lite subset and were used for this purpose as they 
provide a representation of the compounds within the RS subset.  No 
replicates were used for the primary screening of the RS Lite subset or the 
RS subset due to the quantity of compounds screened.  Wild-type K3 iPSC-
derived hepatocyte-like cells were used because they have functional LDLRs 
which allowed for identification of all compounds within the RS subset that 
lowered Apolipoprotein B levels secreted into the culture medium.  
Wild-type K3 iPSC-derived hepatocyte-like cells were differentiated in 
	
Figure 1: Experimental Design Overview 
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96-well format, and samples of culture medium were collected before and 
after the 24-hour compound treatment.  The level of Apolipoprotein B within 
the culture medium was determined by ELISA for the pre- and post-
treatment samples and the concentrations were used to determine the [post-
treatment]:[pre-treatment] ratio of Apolipoprotein B within the culture 
medium (Figure 1).  The ratio of Apolipoprotein B was normalized to the 
average ratio of Apolipoprotein B within the culture medium of DMSO only 
treated control cells. 
 Z-factor analysis was conducted for our ELISA assay to determine the 
efficiency of the assay to distinguish between a positive control (mature iPSC-
derived hepatocyte-like cells) and a 
negative control (undifferentiated 
iPS cells).  The z-factor (Z’) is 
determined by using the formula  
Z’ = !(!!!!!!!)
!!!!!!!
; where 𝜎!!  and 𝜎!! 
are the standard deviations for 
positive and negative controls respectively, and 𝜇!! and 𝜇!! are the averages 
for positive and negative controls respectively.  Readings between 0.5 and 1.0 
indicate that the assay is excellent for high throughput screening 
applications.22  The z-factor reading for our assay was 0.73 (Figure 2).   
Primary screening of the RS Lite subset using wild-type K3 iPSC-
derived hepatocyte-like cells, yielded 25 compounds that significantly lowered 
 
Figure 2: Z-Factor Analysis of ELISA Assay 
Z-Factor Analysis shows the ability of our ELISA 
to distinguish between positive (blue) and 
negative (orange) controls. 
	 12	
Apolipoprotein B secretion in the culture medium as determined by z-score 
analysis using a more lenient threshold of a z-score of -2.0, which corresponds 
to a confidence interval of approximately 95.5% (Primary screening 
normalized ratios and z-scores for RS Lite set are included in Figure 3).  We 
chose to utilize a z-score of -2.0 rather than a z-score of -3.0 as the threshold 
for screening the first 1,000 compounds because we wanted to ensure that we 
were identifying all possible compounds that were likely to significantly lower 
Apolipoprotein B within the culture medium. 
Validation screening with replicates (n=4) of the 25 compounds 
identified in the RS Lite primary screening  resulted in four compounds 
which reduced Apolipoprotein B secretion significantly (p ≤ 0.05) compared to 
DMSO-only treated control cells (Figure 4A).  The four reproducible hits 
were all compounds that had z-scores ≤ -3.0 when originally tested in the 
primary screening.   
 Cell viability analysis of the 25 compounds revealed that two of the 
four compounds identified in the validation screening had a significant 
negative impact to cell viability (p ≤ 0.05) (Figure 4B).  This left two 
compounds from the RS Lite subset which significantly (p ≤ 0.05) reduced 
levels of Apolipoprotein B in the culture medium without a significant 








Figure 3: Primary Screening Data from RS subset of SC3 Library (A) Graph showing the [Post-
treatment]:[Pre-treatment] Apolipoprotein B ratios, normalized to DMSO control cells, identified from 
culture medium samples from the primary screen in wild-type K3 IPSC-derived hepatocyte like cells.  
Each point represents the effect of one compound within the RS subset of the SC3 library. (B) Graph 
showing z-scores correlating to the effect of each compound on the level of Apolipoprotein B secreted into 
the culture medium.  Each point represents one compound from within the RS subset of the SC3 library 
and the red lines demarcate +/- 3.0 which we used as our threshold. 
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Screening of SC3 library in WT K3 Cells 
Following successful identification of compounds that would 
significantly reduce Apolipoprotein B concentrations with the RS Lite subset, 
we continued screening the remainder of the RS subset.  Wild-type K3 iPSC-
derived hepatocyte-like cells were differentiated in 96-well format, and 
samples of culture medium were collected before and after the 24-hour 
compound treatment.  The level of Apolipoprotein B within the culture 
medium was determined by ELISA.  A ratio between [Post treatment ApoB] 
and [Pre treatment ApoB] was determined for all 10,000 compounds in the 
RS subset of the SC3 library (Figure 3A).  Z-scores were also determined for 
each compound (Figure 3B).   
In screening the RS subset, we considered all compounds with z-scores 
≤ -3.0 to be primary hits.  This z-score corresponds to a confidence interval of 
approximately 99.7%.  In analyzing the primary data, we also decided to 
include 13 compounds whose z-scores fell just outside our threshold of z-
scores ≤ -3.0 because we could accommodate additional primary hits in the 
follow-up assays.  All 13 additional compounds added had z-scores between -
2.7 (approximately 99.3% confidence interval) and -3.0, in addition to 
reductions in Apolipoprotein B secretion of at least 25%. This resulted in 44 
compounds that were considered to be primary hits, in addition to the 25 
primary hits previously identified in screening the RS Lite subset of the SC3 
library (the first 1,000 compounds of the RS subset) using a less stringent z-
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A   
B   
Figure 4: RS Validation Screening: (A) shows the normalized Apolipoprotin B secretion ratios 
for all 68 primary hits (n=4). (B) show cell viability assay results for the same samples (n=4). 
Asterisk indicates p ≤ 0.05  
score of z ≤ -2.0, for a total of 69 primary hits within the RS subset of the SC3 
library.  
These 69 compounds had Apolipoprotein B reductions ranging from 
13.8% to 80.2% compared to DMSO-treated control cells.  Validation 
screening of the 68 total primary hits with replicates (n=4) showed 19 total 
compounds that reduced Apolipoprotein B secretion with statistical 
significance (p ≤ 0.05) compared to DMSO-treated control cells (Figure 4A). 
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 In addition to the mechanistic effects of the compounds, observed 
reductions in concentration of Apolipoprotein B in the culture medium could 
also be attributed to a reduction in cell viability as a result of the compound 
toxicity.  Cell viability analysis of the primary hits showed that 11 of the 19 
compounds identified in the validation screening did not have a negative 
impact on cell viability 
(Figure 4B).  The 11 
compounds that significantly 
lowered Apolipoprotein B 
concentrations in the culture 
medium of wild-type K3 
iPSC-derived hepatocyte-like 
cells without negatively 
impacting cell viability are 
listed in Table 1.  
 
Screening in patient-derived HoFH Cells 
 Following the identification of compounds that lowered Apolipoprotein 
B levels in cells that had functional LDLRs without decreasing cell viability, 
we wanted to determine if any of those compounds of interest functioned 
independently of the LDLR.  To test this, we utilized iPSCs derived from a 
patient, JD, who had two characterized mutations7, 23, 24 (compound 
Compound 
Normalized Ratio 
in WT (n=4) 
Cell Viability 
in WT (n=4) 
D-28395 0.778469746 92.88% 
D-67841 0.683902366 105.59% 
D-85697 0.848756691 102.28% 
D-67383 0.685334429 106.14% 
D-26389 0.536272923 104.92% 
D-65895 0.607600512 111.17% 
D-70514 0.75044936 105.84% 
D-70458 0.6974290 93.02% 
D-28929 0.852019837 93.45% 
A-00152 0.787729162 104.69% 
D-65600 0.885846075 99.97% 
Table 1: Compounds of Interest following Validation 
Compounds from the RS set that significantly lowered ApoB 
levels in culture medium of WT K3 IPSC-derived 
hepatocyte-like cells without decreasing the cell viability. 
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heterozygote) to the LDLR gene resulting in an effective homozygous FH 
phenotype that has previously been shown to recapitulate the HoFH 
phenotype in induced hepatocyte-like cells.7  The patient-derived IPSC-
derived hepatocyte-like cells were treated with 10 of the 11 compounds 
previously identified in K3 
cells for 24 hours following a 
pre-treatment sample 
collected (n=3).	  After the 
24-hour treatment, a post-
treatment sample was also 
collected, as before. Analysis 
of these samples showed that 
5 of the 10 compounds tested 
so far significantly reduced 
Apolipoprotein B levels (p ≤ 
0.05) in the presence of 
nonfunctional LDLRs 
(Figure 5A) without 
decreasing the cell viability (Figure 5B).  The compounds had reductions in 
Apolipoprotein B levels ranging from 16.67% to 43.6% compared to DMSO-




Figure 5: Normalized Ratios and Cell Viability in 
Patient-Derived IPS Cells (A) Average [Post-treatment 
ApoB] : [Pre-treatment ApoB] ratios normalized to DMSO-
treated control cells (n=3) for compounds treated on 
patient-derived HoFH IPSC-derived hepatocyte-like cells. 
Asterisk indicates p ≤ 0.05  (B) Cell viability normalized to 
DMSO-treated control cells (n=3) for compounds treated 
on patient-derived HoFH IPSC-derived hepatocyte-like 




In conducting this research, we have identified 11 novel compounds, 5 
of which we believe to function independent of the LDLR, that may have the 
potential to be used in the future as therapies for patients with 
hypercholesterolemia.  	
Previous research in our lab determined that cardiac glycosides have a 
cholesterol lowering effect.9  Identification of the chemical structures of our 
compounds of interest following this screening showed four of the compounds 
to be chemically similar to cardiac glycosides (D-14442, D-67844, D-82034, 
and D-83522).  All four of these compounds significantly lowered 
Apolipoprotein B concentrations (p ≤ 0.05) within culture medium of wild-
type K3 iPSC-derived hepatocyte-like cells; however, they were also observed 
to reduce cell viability significantly (p ≤ 0.05).  The compound D-82034 was 
also tested in the patient-derived JD HoFH iPSC-derived hepatocyte-like 
cells (data not shown) and was seen to significantly lower Apolipoprotein B 
concentrations (p ≤ 0.05).  Cell viability analysis showed 68.3% viability for 
the compound D-82034 in patient-derived JD HoFH iPSC-derived hepatocyte-
like cells.  In the wild-type cell line, the cell viability analysis for the 
glycoside-like compounds D-14442, D-67844, D-82034, and D-83522 showed 
37.71%, 6.14%, 72.02%, and 73.51% cell viabilities respectively.  The previous 
research in our lab found that treatment with cardiac glycosides in the 
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nanomolar range was sufficient to observe significant reduction in 
Apolipoprotein B concentration.9  In screening the RS subset of the SC3 
library, we used 5.2 µM concentrations in our compound treatment.  
Therefore, it is likely that at a lower concentration these four compounds may 
not have a significant negative impact to cell viability. 	
The patient-derived JD HoFH iPSC-derived hepatocyte-like cells have 
been shown to have nonfunctional LDL receptors that do not internalize 
LDL-C.9  As a result of this, it can be hypothesized that the compounds which 
were shown to lower Apolipoprotein B levels in the patient-derived JD HoFH 
IPSC-derived hepatocyte-like cells (D-85697, D-67383, D-65895, and D-28395, 
D-70514), function through mechanisms that are LDLR-independent. It is 
likely that these compounds function to reduce Apolipoprotein B 
concentrations by decreasing the production of Apolipoprotein B, increasing 
the degradation of Apolipoprotein B, or interfering with the ability of 
Apolipoprotein B to form lipoprotein particles, any of which would result in 
decreased levels of Apolipoprotein B within the culture medium. 
Additionally, there was one compound, D-70458, that was also shown 
to significantly reduce Apolipoprotein B levels; however, a 69% reduction in 
cell viability was observed.  Reduced cell viability was not previously 
observed with this compound.  It is possible that the compound has degraded 
as a result of several cycles of thawing and refreezing the compound during 
the course of this screen.  We plan to retreat this compound on the patient-
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derived cell line in the future, in addition to testing the remaining compound 
that was identified in the wild-type validation screening, D-28929, that has 
not yet been exposed to the patient-derived cell line.	
There were eight compounds that were observed to significantly reduce 
Apolipoprotein B concentrations in the culture medium of wild-type K3 iPSC-
derived hepatocyte-like cells but were excluded from testing in the patient-
derived cell line because of their impact to cell viability in the wild-type K3 
iPS cell line.  Four of the eight compounds excluded from screening in the 
patient derived JD HoFH iPS cell line were the previously mentioned 
glycoside-like compounds. In future research, dose response will be conducted 
on all of the compounds identified to significantly reduce Apolipoprotein B 
concentrations in wild-type K3 iPSC-derived hepatocyte-like cells to 
determine if adjusting the dosage of the compound mitigates any negative 
impact on cell viability.	
Because the RS subset that we used in our screen was constructed to 
be chemically representative of the entire SC3 library, we can return to the 
full library of 120,000 compounds in the future and selectively screen other 
compounds that are chemically similar to the hits that we identified in 
screening the RS subset.  This process could identify other compounds that 
lower Apolipoprotein B concentrations that were not already identified in 
screening the RS subset.  Congruent results between the hits identified in the 
RS screen and their respective chemically similar compounds would increase 
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our confidence in our results.  It is possible that there are similar compounds 
in the full library that lower Apolipoprotein B levels more dramatically or 
with less effect on the cell viability that would also be of interest.	
Although these compounds were identified to lower Apolipoprotein B 
levels in culture medium, it is possible that the compounds within the library 
are not entirely pure.  Contamination of the compound could play a role in 
the reduction of Apolipoprotein levels, leading to a need to determine the 
purity of the compounds we identified.	
Although iPSC-derived hepatocyte-like cells provided a suitable 
platform for high throughput screening of a large number of compounds, 
these cells don’t express the full array of mRNAs that are seen in adult 
primary hepatocytes.15  This discrepancy in mRNA profiles between iPSC-
derived hepatocyte-like cells and primary human hepatocytes could impact 
drug metabolism and efficacy.  Testing the compounds of interest in primary 
human hepatocytes would provide key information to better understand how 
these compounds may behave in the context of the human system.  
Additionally, due to their availability, we are choosing not to focus on the 
glycoside-like compounds.  Testing our compounds of interest in an iPS cell 
line containing a mutation to the ATP1a1 gene would allow us to screen out 
compounds that function through the same mechanism as cardiac glycosides 
because the ATP1a1 mutation present in this cell line prevents the binding of 
cardiac glycosides to their receptor.25	
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In order to determine the mechanism of action for our compounds of 
interest, it is necessary to determine at which point in the pathway of 
cholesterol biosynthesis and secretion the compounds exert their influence.  
Conducting tests such as qRT-PCR and immunoblotting would provide 
information about the levels of mRNA and protein expression for genes 
related to cholesterol synthesis, such as Apolipoprotein B, PCSK9, and 
MTTP, which would be useful in determining where along the pathway the 
compounds are acting and whether they act before or after transcription or 
translation.  Structure-activity relationship (SAR) testing would also help to 
elucidate more specifically the action by which the compound reduces 
Apolipoprotein B by comparing the chemical structures of our compounds of 
interest to other structures with known mechanisms.  This could provide 
some insight into specific targets for the compounds of interest within 
cellular pathways.  Additionally, comparison of our compounds of interest to 
known compounds could provide information regarding adverse effects 
associated with specific structural components present in our compounds of 
interest.  Further information regarding potential toxic side effects of our 
compounds of interest could be obtained by testing the compounds in other 
major cell types such as cardiomyocytes or neural cells.  Treatment of our 
lead compounds in mice with humanized livers would allow for identification 
of the compounds’ effectiveness in a more complex system as well as allowing 
	 23	
for identification of potential adverse effects of the compounds on the level of 
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